Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Should You Buy?

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) gapped up before the market opened on Tuesday . The stock had previously closed at $3.51, but opened at $3.72. Autolus Therapeutics shares last traded at $3.53, with a volume of 393,016 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a research report on Monday.

Autolus Therapeutics Trading Down 1.2 %

The business has a 50-day simple moving average of $3.95 and a 200-day simple moving average of $4.00. The company has a market cap of $875.44 million, a PE ratio of -2.72 and a beta of 2.04. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the firm posted ($0.26) EPS. On average, analysts predict that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of AUTL. ProShare Advisors LLC acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth about $43,000. Daiwa Securities Group Inc. raised its holdings in Autolus Therapeutics by 2,659.7% during the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. Herbst Group LLC purchased a new stake in shares of Autolus Therapeutics during the 3rd quarter worth approximately $91,000. Bayesian Capital Management LP acquired a new position in shares of Autolus Therapeutics in the 1st quarter valued at $100,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in Autolus Therapeutics during the 1st quarter worth $108,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.